Siemens Healthineers has introduced its teamplay digital health platform, which features a data sharing and connectivity service, an interoperability module, and a marketplace for artificial intelligence (AI) applications.
Teamplay is a vendor-, system-, and device-neutral platform designed to foster interoperability, data integration, and analytics across departments and institutions, according to the company. It can be deployed via the cloud, on-premises, and in hybrid deployments based on edge computing, Siemens said.
The marketplace will provide users with access to decision-support software from Siemens, as well as third-party AI applications. New Siemens applications have been added to the platform, including teamplay Insights, AI-Rad Companion Chest X-Ray, AI-Pathway Companion Lung Cancer, and teamplay myCare Companion.
Teamplay Insights enables the creation of personalized dashboards, while AI-Rad Companion Chest X-Ray is designed to help radiologists read images faster and more accurately and to reduce the time needed to document results, according to the firm. AI-Pathway Companion Lung Cancer is a clinical decision-support application that aids physicians such as oncologists and pulmonologists in making diagnostic and therapeutic decisions.
The last new offering, teamplay myCare Companion, is a telehealth application that provides information to both care teams and patients with chronic diseases such as heart failure, Siemens said. It also supports care management programs.
![A normal mammogram confirmed by three-year radiologic follow-up illustrates reader-marked regions of interest (ROIs) during (A) unaided (round 1) and (B) artificial intelligence (AI)–assisted (round 2) reading. Each colored dot represents an ROI for recall by a human reader. Readers could mark more than one ROI per case, represented by multiple dots of the same color. During AI-assisted reading, the AI system displayed three visible prompts: two with suspicion of malignancy scores of 35% (left mediolateral oblique [L MLO] and craniocaudal [L CC]) and one with a suspicion of malignancy score of 10% (right craniocaudal [R CC]), shown as polygonal overlays. Without AI, six of 10 readers (60%) marked a false-positive ROI. With AI assistance, this fell to two of 10 (20%). R MLO = right mediolateral oblique.](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/07/2026-07-14-radiology-mammogram-ai-auto-bias.H0bYO8QlWs.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
